Victrelis(boceprevir)
Victrelis (boceprevir) is a small molecule pharmaceutical. Boceprevir was first approved as Victrelis on 2011-05-13. It is used to treat chronic hepatitis c and hepatitis c in the USA. It has been approved in Europe to treat chronic hepatitis c. It is known to target lysosomal protective protein.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Boceprevir
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VICTRELIS | Merck Sharp & Dohme | N-202258 DISCN | 2011-05-13 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| chronic hepatitis c | EFO_0004220 | D019698 | B18.2 |
| hepatitis c | — | D006526 | B19.2 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
61 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronary artery disease | D003324 | I25.1 | — | — | 2 | 7 | 1 | 10 | |
| St elevation myocardial infarction | D000072657 | — | — | 1 | 6 | 2 | 9 | ||
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | 3 | 3 | — | 6 | |
| Coronary disease | D003327 | — | 1 | — | 3 | 2 | 6 | ||
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | 3 | 2 | — | 5 |
| Percutaneous coronary intervention | D062645 | — | — | 1 | 3 | — | 4 | ||
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | 2 | 1 | — | 3 |
| Inferior wall myocardial infarction | D056989 | EFO_1000983 | — | — | 2 | 1 | — | 3 | |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | — | — | 1 | — | 1 |
| Aging | D000375 | GO_0007568 | R41.81 | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronary artery bypass | D001026 | EFO_0003776 | — | — | 4 | — | — | 4 | |
| Thrombosis | D013927 | — | 1 | 2 | — | — | 3 | ||
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 2 | — | — | 2 |
| Unstable angina | D000789 | EFO_1000985 | I20.0 | — | — | 1 | — | — | 1 |
| Acute disease | D000208 | — | — | 1 | — | — | 1 | ||
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | — | — | 1 | — | — | 1 |
| Aortic valve stenosis | D001024 | EFO_0000266 | Q25.1 | — | — | 1 | — | — | 1 |
| Transcatheter aortic valve replacement | D065467 | — | — | 1 | — | — | 1 | ||
| Non-st elevated myocardial infarction | D000072658 | — | — | 1 | — | — | 1 | ||
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Venous thrombosis | D020246 | HP_0004936 | I82.40 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | — | 1 | 1 |
| Covid-19 | D000086382 | U07.1 | — | — | — | — | 1 | 1 | |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | BOCEPREVIR |
| INN | boceprevir |
| Description | Boceprevir is a synthetic tripeptide consisting of N-(tert-butylcarbamoyl)-3-methyl-L-valyl, a cyclopropyl-fused prolyl and 3-amino-4-cyclobutyl-2-oxobutanamide residues joined in sequence. Used for treatment of chronic hepatitis C virus genotype 1 infection. It has a role as a hepatitis C protease inhibitor, a peptidomimetic and an antiviral drug. It is a tripeptide and a member of ureas. |
| Classification | Small molecule |
| Drug class | antivirals: serine protease inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C |
Identifiers
| PDB | — |
| CAS-ID | 394730-60-0 |
| RxCUI | 1102129 |
| ChEMBL ID | CHEMBL218394 |
| ChEBI ID | 68621 |
| PubChem CID | 10324367 |
| DrugBank | DB08873 |
| UNII ID | 89BT58KELH (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CTSA
CTSA
Organism
Homo sapiens
Gene name
CTSA
Gene synonyms
PPGB
NCBI Gene ID
Protein name
lysosomal protective protein
Protein synonyms
beta-galactosidase 2, beta-galactosidase protective protein, Carboxypeptidase C, Carboxypeptidase L, carboxypeptidase Y-like kininase, carboxypeptidase-L, Cathepsin A, deamidase, lysosomal carboxypeptidase A, PPCA, Protective protein cathepsin A, Protective protein for beta-galactosidase, urinary kininase
Uniprot ID
Mouse ortholog
Ctsa (19025)
lysosomal protective protein (Q8VEF6)
Variants
Clinical Variant
Identifier | Target mutation | Effect | Evaluation | Status |
|---|---|---|---|---|
| VCV000225949 | IFNL4, 151-152G>A | drug response | 2021-03-24 | 1A |
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,898 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,281 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more